Select Page
Sustainable access to effective antibiotics - what should the EU do?
EPHA #A2MDialogues

15 April 2021

16:00-17:00 CET

online

Continuing our successful online discussions on key access to medicines (A2M) priorities bringing together thought leaders and policy-makers, academics, industry representatives and NGOs, for a frank discussion of European pharmaceutical policies.

Take part in our #A2MDialogues to share your questions and ideas and help us develop actionable #A2Msolutions for decision-makers in Europe.

How can we solve the AMR epidemic? What is the role of the EU?

What can HERA do?

The scientific and structural difficulties in discovering new antibiotics have only begun to be appreciated in recent years, while discussions on how to overcome financial bottlenecks have gathered much attention. To overcome these scientific barriers, the public sector needs to get involved to get the highest priority antibiotics, diagnostics and vaccines developed.

We need a new alternative to the traditional patent-based business model, where the return on investment does not depend on high volume sales or high prices of novel antibiotics. Importantly, we need to have strategies in place to minimize their unnecessary use to keep them effective for as long as possible and ensure they are affordable for those in need from the onset of the development process.

Join our panel to discuss how to foster R&D of new antimicrobial therapies, diagnostics and vaccines in order to replace antibiotics rendered ineffective by AMR, reduce unnecessary use of antibiotics and prevent infections.

#A2MDialogues

Our Panel

Helle Aagaard

Deputy Director

ReAct – Action on Antibiotic Resistance (Europe) 

Rohit Malpani

Public Health Consultant

Timothy Jinks 

Head, Drug Resistant Infections Programme

Wellcome Trust

Moderated by

Yannis Natsis,

Policy Manager, Universal Access to Affordable Medicines

European Public Health Alliance

Catch up on EPHA’s other #A2MDialogues below

After COVID-19, what's next for EU medicines policies?

9 March 2021

Getting it right: Recommendations for a European BARDA

8 December 2020

The The Presidencies’ perspective on the pharmaceutical strategy: Europe’s to-do list on access to medicines

25 November  2020

Pharma & COVID19: Winners, losers, prospects

19 November  2020

The EU's IP strategy: Enabler or barrier?

27 October 2020

Unleashing meaningful innovation through regulatory reform

19 October 2020

Follow on social media

#A2MDialogues

#A2Msolutions

Contact

Yannis Natsis

Policy Manager, Universal Access and Affordable Medicines, EPHA
yannis@epha.org